Skip to content
Search

Latest Stories

India's mobile internet use increases ninefold

Mobile internet usage in India has increased ninefold in a single year, after the launch of a new operator sparked a telecoms price war, according to a new report.

Indians used nearly 1.3 billion gigabytes of data in March 2017 compared with around 150 million in the same period last year, said the report, Internet Trends 2017, published this week by the US investment fund Kleiner Perkins.


The explosion in data use comes after the country's richest man Mukesh Ambani, shook up the telecoms market with the launch of new operator Jio in September.

The 4G telecom operator launched with an offer of free service for the rest of the year, followed by vastly cheaper data plans and free voice calls for life.

That led to a dramatic fall in the average cost of mobile internet in India, which the study said was 1.9 dollars in March compared to 4.4 dollars three years earlier.

By March this year Jio had 108 million subscriber, and was charging just 17 cents per giga of data.

Despite regulatory and technical obstacles, India's mobile internet market has huge growth potential with hundreds of millions expected to get online over the next decade using smartphones.

The country counts one billion mobile phone users, but nearly three-quarters of its population lacks access to the internet. In 2016, only 350 million Indians were able to go online.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less